Author

Guido Papa

University of MilanORCID 0000-0002-5215-0014Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Abeer MahfoudiD· 1 shared Adam KirbyiD· 1 shared Alessio Nicola FerraroiD· 1 shared Alice RandoniD· 1 shared Andrew OweniD· 1 shared Brian McGuinnessiD· 1 shared Edoardo ScarpaiD· 1 shared Eduardo Gallardo ToledoiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Abeer MahfoudORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintAug 3, 2026

A vesicle-based platform for high-efficiency, high-viability CRISPR/Cas9 knockout in primary human myeloid cells

Silvia Fiori, Maira Russo, Alice Randon…·Manuel Albanese

This paper develops a vesicle-based CRISPR/Cas9 platform for efficient gene knockout in primary human myeloid cells, preserving viability and enabling downstream functional studies.

DOI 10.64898/2025.12.28.696771

humanCRISPR screen

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintOct 3, 2025

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings

Maximilian A. J. Harman, Katherine U. Gaynor, Guido Papa…·Michael J. Skynner

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

DOI 10.1101/2025.10.03.680220

mouseexperimental assay

𝕏 PostBluesky